Ixazomib, lenalidomide, and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma

Ixazomib, lenalidomide, and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma

Ixazomib is approved for use in combination with lenalidomide and dexamethasone (IRd) for patients with multiple myeloma (MM) who received at least one previous therapy. Registration study “TOURMALINE MM-1” was published in 2016. Nevertheless, clinical trials are significantly different from real-wo...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology Vol. 101; no. 1; pp. 81 - 89
Main Authors: Sokol, Juraj, Guman, Tomas, Chudej, Juraj, Hlebaskova, Monika, Stecova, Natalia, Valekova, Lubica, Kucerikova, Monika, Stasko, Jan
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 2022
Springer Nature B.V
Subjects:
Adult
Aged
Anemia - chemically induced
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Boron Compounds - adverse effects
Boron Compounds - therapeutic use
Cohort Studies
Dexamethasone - adverse effects
Dexamethasone - therapeutic use
Female
Glycine - adverse effects
Glycine - analogs & derivatives
Glycine - therapeutic use
Hematology
Humans
Immunotherapy
Kaplan-Meier Estimate
Lenalidomide - adverse effects
Lenalidomide - therapeutic use
Male
Medicine
Medicine & Public Health
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - epidemiology
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - epidemiology
Neutropenia - chemically induced
Oncology
Original Article
Slovakia - epidemiology
Steroids
Targeted cancer therapy
Slovakia
Effectiveness
Safety
Ixazomib
Relapsed/refractory
Multiple myeloma
Real-world data
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ixazomib is approved for use in combination with lenalidomide and dexamethasone (IRd) for patients with multiple myeloma (MM) who received at least one previous therapy. Registration study “TOURMALINE MM-1” was published in 2016. Nevertheless, clinical trials are significantly different from real-world use. From June 2016 to December 2018, IRd was available for Slovak patients with relapsed/refractory MM through a Named Patient Program. The aim of this study was to evaluate the efficacy and safety of ixazomib. We analyzed in this cohort study outcomes of 106 MM patients treated with IRd at 2 academic centers. The median age at diagnosis was 63 years (44–78). The median number of prior lines was 2 (1–7). The majority had high international staging system (ISS) score: 18, 29, and 59 were in the ISS I, ISS II, and ISS III groups, respectively. Treatment continued until progression, unacceptable toxicity, or death. The median follow-up for the entire cohort was 29 (0–49) months. The overall response rate was 74.5% (complete remission, 7.5%; partial remission, 67%). The median overall survival was not reached. Median progression-free survival (PFS) was 43 months (95% CI 35.6–50.4). The Kaplan–Meier method was used to generate survival curves, and we compared the influence of different factors on PFS. The most common hematological adverse events of any grade were neutropenia (90.4%), anemia (55.6%), and thrombocytopenia (43.4%). Our real-world data support the use of IRd as a highly effective and well-tolerated oral treatment protocol for relapsed myeloma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-021-04663-0